Ovarian cancer drug combo trial halted early
NCT ID NCT05200364
First seen Oct 31, 2025 · Last updated May 06, 2026 · Updated 30 times
Summary
This early-stage trial tested a new drug (STRO-002) combined with bevacizumab in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the best dose. The study was terminated, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19017, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of South Florida,
Tampa, Florida, 33612, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.